Clinical Trial Update: First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating first-line EXL01 with nivolumab and FOLFOX for PD-L1 CPS ≥5 metastatic gastric cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• EXL01
• FOLFOX
• nivolumab (nivolumab)

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: Gastric Cancer | Phase 2 | Status: RECRUITING